Arrowhead Pharmaceuticals stock forecast
Arrowhead Pharmaceuticals (HDP1) Stock Forecast & Price Target
HDP1 Analyst Ratings
HDP1 Stock 12 Month Forecast
Average Price Target
CHF89.55▲(78.71% Upside)Detailed List of Analyst Forecasts​
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Eric Joseph | Citi | CHF90.77→CHF88.25 | buy | 76.10%Upside | Reiterated | 11/17/26 | ||
| Edward Tenthoff | Piper Sandler | CHF105.90 | buy | 111.32%Upside | Reiterated | 11/13/26 | ||
| James Condulis | Stifel Nicolaus | CHF87.41→CHF80.68 | buy | 61.00%Upside | Reiterated | 11/13/26 | ||
| UBS | CHF91.61 | buy | 82.81%Upside | Reiterated | 11/13/26 | |||
| Michael Ulz | Morgan Stanley | CHF100.85→CHF89.09 | buy | 77.78%Upside | Reiterated | 11/13/26 | ||
| Luca Issi | RBC Capital | CHF84.04 | buy | 67.71%Upside | Reiterated | 11/13/26 | ||
| Jason Gerberry | Bank of America Securities | ― | buy | ― | Reiterated | 11/13/26 | ||
| Patrick Trucchio | H.C. Wainwright | CHF100.85 | buy | 101.26%Upside | Reiterated | 11/11/26 | ||
| Madison Elsaadi | B. Riley Securities | CHF103.37 | buy | 106.29%Upside | Reiterated | 11/10/26 | ||
| Brian Cheng | J.P. Morgan | ― | buy | ― | Reiterated | 10/15/26 | ||
| Andrea Newkirk | Goldman Sachs | CHF62.19 | hold | 24.11%Upside | Initiated | 09/24/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 08/30/26 | ||
| Keay Nakae | Chardan Capital | CHF96.65 | buy | 92.87%Upside | Reiterated | 08/04/26 | ||
| William Pickering | Bernstein | CHF29.42→CHF38.66 | hold | -22.85%Downside | Assigned | 05/13/26 | ||
| Mani Foroohar | Leerink Partners | ― | hold | ― | Reiterated | 03/26/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Eric JosephCiti | BuyReiteratedCHF90.77→CHF88.25 | 11/17/26 | 76.10%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiteratedCHF105.90 | 11/13/26 | 111.32%Upside | ||
| James CondulisStifel Nicolaus | BuyReiteratedCHF87.41→CHF80.68 | 11/13/26 | 61.00%Upside | ||
| BuyReiteratedCHF91.61 | 11/13/26 | 82.81%Upside | |||
| Michael UlzMorgan Stanley | BuyReiteratedCHF100.85→CHF89.09 | 11/13/26 | 77.78%Upside | ||
| Luca IssiRBC Capital | BuyReiteratedCHF84.04 | 11/13/26 | 67.71%Upside | ||
| Jason GerberryBank of America Securities | BuyReiterated | 11/13/26 | ― | ||
| Patrick TrucchioH.C. Wainwright | BuyReiteratedCHF100.85 | 11/11/26 | 101.26%Upside | ||
| Madison ElsaadiB. Riley Securities | BuyReiteratedCHF103.37 | 11/10/26 | 106.29%Upside | ||
| Brian ChengJ.P. Morgan | BuyReiterated | 10/15/26 | ― | ||
| Andrea NewkirkGoldman Sachs | HoldInitiatedCHF62.19 | 09/24/26 | 24.11%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated | 08/30/26 | ― | ||
| Keay NakaeChardan Capital | BuyReiteratedCHF96.65 | 08/04/26 | 92.87%Upside | ||
| William PickeringBernstein | HoldAssignedCHF29.42→CHF38.66 | 05/13/26 | -22.85%Downside | ||
| Mani ForooharLeerink Partners | HoldReiterated | 03/26/26 | ― |
Best Analysts Covering Arrowhead Pharmaceuticals
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +25.56% per trade.
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +105.55% per trade.
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 62.07% of your transactions generating a profit, with an average return of +63.43% per trade.
HDP1 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 1 | 7 | 16 |
| Buy | 30 | 35 | 33 | 20 | 6 |
| Hold | 1 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 32 | 35 | 35 | 28 | 23 |
In the current month, HDP1 has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HDP1 average Analyst price target in the past 3 months is 89.55.
HDP1 Financial Forecast
HDP1 Earnings Forecast
Next quarter’s earnings estimate for HDP1 is -CHF 1.22 with a range of -CHF 1.48 to -CHF 0.80. The previous quarter’s EPS was -CHF 2.55. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HDP1 Sales Forecast
Next quarter’s sales forecast for HDP1 is CHF 40.92M with a range of CHF 16.81M to CHF 100.96M. The previous quarter’s sales results were CHF 31.76M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
